Galangin ameliorates experimental autoimmune encephalomyelitis in mice via modulation of cellular immunity

Simple item page
dc.contributor.authorTan, Kok-Tongen
dc.contributor.authorLi, Shimingen
dc.contributor.authorPanny, Laurenen
dc.contributor.authorLin, Chi-Chienen
dc.contributor.authorLin, Shih-Chaoen
dc.contributor.departmentBiomedical Sciences and Pathobiologyen
dc.date.accessioned2021-04-21T17:16:00Zen
dc.date.available2021-04-21T17:16:00Zen
dc.date.issued2021-03-23en
dc.description.abstractMultiple sclerosis (MS) causes neurologic disabilities that effect musculature, sensory systems, and vision. This is largely due to demyelination of nerve fibers caused by chronic inflammation. Corticosteroid treatments ameliorate symptoms of MS, but do not successfully cure the disease itself. In the current study, the application of galangin, a phytochemical flavonoid extracted from the ginger family of Alpinis officinarum, on experimental autoimmune encephalomyelitis (EAE; mouse model for MS) was explored. This study investigated prophylactic and therapeutic activity of the drug and mechanisms by which it acts. The results revealed that galangin at 40 and 80 mg/kg could lower the incidence rate of MS, and alleviate clinical/pathological manifestations. Mice administered galangin presented with less limb paralysis, lower levels of inflammatory cell infiltrates, and decreased demyelination compared to vehicle controls. Levels of CD4(+)IFN gamma(+) (T(H)1) and CD4(+)IL-17A(+) (T(H)17) cells in the spinal cords of EAE mice administered galangin were reduced and both cell types were not capable of expansion. More surprisingly, galangin inhibited antigen presentation and cytokine production by dendritic cells (DC). Formation of cytokines like IL-6, IL-12, and IL-23 were significantly decreased due to galangin in co-culture models of DC and T-cells. Taken together, the data lead one to conclude that galangin could potentially be used as a potent immunoregulatory agent to alleviate clinical symptoms and reduce the prevalence of MS.en
dc.description.notesThis study was supported by grants from the Taichung Veterans General Hospital (#TCVGH-1097309C) and the Animal Biotechnology Center from the Feature Areas Research Center Program of Taiwan Ministry of Education (#MOE-107-S-0023-E).en
dc.description.sponsorshipTaichung Veterans General Hospital [TCVGH-1097309C]; Animal Biotechnology Center from the Feature Areas Research Center Program of Taiwan Ministry of Education [MOE-107-S-0023-E]en
dc.format.mimetypeapplication/pdfen
dc.identifier.doihttps://doi.org/10.1080/1547691X.2021.1890863en
dc.identifier.eissn1547-6901en
dc.identifier.issn1547-691Xen
dc.identifier.issue1en
dc.identifier.pmid33770444en
dc.identifier.urihttp://hdl.handle.net/10919/103068en
dc.identifier.volume18en
dc.language.isoenen
dc.rightsCreative Commons Attribution-NonCommercial 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/en
dc.subjectGalanginen
dc.subjectexperimental autoimmune encephalomyelitis (EAE)en
dc.subjectT cellsen
dc.subjectdendritic cellsen
dc.subjectanti-inflammationen
dc.titleGalangin ameliorates experimental autoimmune encephalomyelitis in mice via modulation of cellular immunityen
dc.title.serialJournal of Immunotoxicologyen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten
dc.type.dcmitypeStillImageen

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
TanGalangin2021.pdf
Size:
3.07 MB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

Scholarly Works, Biomedical Sciences and Pathobiology
Destination Area: Adaptive Brain and Behavior (ABB)